Lazard Asset Management
AXSM icon

Lazard Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Lazard Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.22M Sell
13,163
-247
-2% -$42.7K ﹤0.01% 842
2025
Q4 		$2.45M Sell
13,410
-8,427
-39% -$1.18M ﹤0.01% 786
2025
Q3 		$2.65M Sell
21,837
-7,456
-25% -$840K ﹤0.01% 768
2025
Q2 		$3.06M Buy
29,293
+44
+0.2% +$4.66K ﹤0.01% 873
2025
Q1 		$3.41M Sell
29,249
-508,420
-95% -$57.9M 0.01% 805
2024
Q4 		$45.5M Buy
537,669
+451,737
+526% +$41.5M 0.07% 208
2024
Q3 		$7.72M Buy
+85,932
New +$7.5M 0.01% 524

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lazard Asset Management's AXSM Position: Q1 2026 in Review

Lazard Asset Management reduced its Axsome Therapeutics (AXSM) stake by 1.8% in Q1 2026, selling an estimated $42.7K and leaving 13,163 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #842.

Lazard Asset Management first reported a position in AXSM in Q3 2024 and has held it in 7 quarters since. The position peaked at $45.5M in Q4 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Lazard Asset Management held 13,163 shares of Axsome Therapeutics worth $2.22M as of Q1 2026.
  • Lazard Asset Management sold 247 Axsome Therapeutics shares in Q1 2026, an estimated $42.7K.
  • Axsome Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #842 holding.
  • Lazard Asset Management first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Lazard Asset Management's Axsome Therapeutics position peaked at $45.5M in Q4 2024.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.